Education
About Us
Working with TipRanks
Follow Us
Poniard Pharmaceuticals (PARD)
OTHER OTC:PARD
PARD Stock Chart & Stats
$0.31
>-$0.01(-99.00%)
At close: 4:00 PM EST
$0.31
>-$0.01(-99.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume125.00
Average Volume (3M)N/A
Market Cap
$150.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta180.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,499,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PARD FAQ
What was Poniard Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Poniard Pharmaceuticals’s market cap?
Poniard Pharmaceuticals’s market cap is $150.00.
When is Poniard Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Poniard Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Poniard Pharmaceuticals overvalued?
According to Wall Street analysts Poniard Pharmaceuticals’s price is currently Overvalued.
Does Poniard Pharmaceuticals pay dividends?
Poniard Pharmaceuticals does not currently pay dividends.
What is Poniard Pharmaceuticals’s EPS estimate?
Poniard Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poniard Pharmaceuticals have?
Poniard Pharmaceuticals has 1,499,000 shares outstanding.
What happened to Poniard Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Poniard Pharmaceuticals?
Currently, no hedge funds are holding shares in PARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Technical Analysis
Scinai Immunotherapeutics
―
PainReform
―
MSP Recovery
―
NewcelX
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---